ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate

We are ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate CAS:81926-94-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Synonyms:
(all-Z)
cis-4,7,10,13,16,19-docosahexaneoic acid ethyl ester
ethyl-ester all cis 4,7,10,13,16,19-docosahexaenoate
Doconexent [inn]
Ethyl (all-Z)-docosa-4,7,10,13,16,19-hexaenoate
(5Z,8Z,11Z,14Z)-5,8,11,14-Eicosatetraenoic Acid Ethyl Ester-d5
Docosahexanoic acid-[D5]-ethylester
DHA ethyl ester
4,7,10,13,16,19-docosahexaenoic acid ethyl ester
4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid ethyl ester
Docosahexaenoic Acid Ethyl Ester
 
Molecular Formula: C24H35O2-
Molecular Weight:  355.53400

Items of Analysis Standard of Analysis Test Results
Appearance Colorless to light yellow clear liquid Conform
Assay (GC) ≥98.0% 98.37%
Acid value mgKOH/g ≤2 0.9
Peroxide meq/kg ≤20 2.1
Conclusion Conforms to Factory Standard
 


ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate


Related News: On the basis of achieving low-cost and high-quality processes, production capacity will become the core driving force for API companies to break through sales bottlenecks.Kalium-N-(N-methyl-anthraniloyl)-anthranilat The CTSuccess service uses Catalent’s proprietary StartScoreTM evaluation tool to calculate the complexity of a potential clinical project across more than a dozen specific and objective study characteristics.(Z)-2-(3-Bromo-2-oxo-5,6,7,8-tetrahydro-2H-quinolin-1-yl)-but-2-enedioic acid Britons being brought from Wuhan to the UK are being placed in quarantine at Arrowe Park Hospital in the Wirral, northwest England, Raab said.ethyl 4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)butanecarboximidate hydrochloride In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.“CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.

Related Products
Product Name
Antioxidant 3114 View Details
9-(4-broMophenyl)-10-(naphthalen-1-yl)anthracene View Details
4-(Trifluoromethoxy)benzyl alcohol View Details
Glycyl-L-Leucine manufacturer 2-Fluoro-3-methylBenzonitrile manufacturer [2-chloro-6-fluoro-4-(trifluoromethyl)phenyl]hydrazine manufacturer Tetramethylammonium hydroxide manufacturer quinoxalin-2-ol manufacturer